Valneva SE Business Summary

Valneva SE (VALN) is a specialty biotechnology firm that generates revenue through a multi-pronged model centered on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet needs. Its primary revenue stream is derived from its commercialized vaccine portfolio, which includes IXIARO (Japanese encephalitis), DUKORAL (cholera/ETEC), and IXCHIQ, the world’s first approved single-shot chikungunya vaccine. The company also captures value through strategic R&D partnerships—most notably a high-profile collaboration with Pfizer for the Lyme disease candidate VLA15—and licensing agreements, such as its deal with the Serum Institute of India. Valneva’s business is segmented into Commercialized Vaccines, Vaccine Candidates (R&D), and Technologies and Services, with a strategic pivot toward high-margin proprietary products as it phases out third-party distribution. In the competitive landscape, Valneva contends with Bavarian Nordic in the travel and chikungunya markets, as well as global giants like GSK and Merck & Co. in the broader infectious disease space. It distinguishes itself as a mid-cap specialist that successfully bridges the gap between early-stage biotech innovation and large-scale pharmaceutical commercialization. Valneva was established in 2013 through the merger of Intercell AG and Vivalis SA, led by founding President and current CEO Thomas Lingelbach, an industry veteran with over 30 years of experience at Novartis and Chiron. The executive leadership team includes CFO Peter Bühler, who brings a deep pedigree from Eli Lilly and Merck Serono, and Chief Scientific Officer Hanneke Schuitemaker, a former Janssen executive who joined in 2024 to spearhead the company’s viral vaccine innovation. Other key members include COO Vincent Dequenne and CMO Dr. Juan Carlos Jaramillo. The company is supported by a robust Board of Directors chaired by Anne-Marie Graffin, featuring prominent industry figures such as James Sulat (former CFO of Chiron) and Dr. Kathrin Jansen (former Head of Vaccine R&D at Pfizer). Notable institutional backing includes a significant equity stake from Pfizer and representation from Bpifrance, providing the company with the financial stability and clinical expertise required to navigate late-stage global trials and product launches.